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Methotrexate as a single agent for treating pulmonary 
sarcoidosis: a single centre real-life prospective study
Metotreksat w monoterapii w leczeniu sarkoidozy płucnej: doświadczenia własne 
This work was carried out within the statutory activity of the National Research Institute of Tuberculosis and Lung Diseases, Warsaw. 
Protocol approval number by the local Ethical Committee: KE-31/2004
Abstract
Introduction: The first-line therapy in chronic sarcoidosis, according to WASOG/ATS/ERS recommendations, is GCS. This therapy 
is associated with significant adverse effects and finally does not alter the natural history of the disease. The objective of our study 
was to evaluate the efficacy and safety of monotherapy with MTX, as an alternative to GCS, in progressive pulmonary sarcoidosis.
Material and methods: An open prospective real-life, single-centre trial was performed on 50 patients with biopsy proven sarcoido-
sis, 28M and 22F, mean age 45.55 ± 8.9 years. The average duration of disease before MTX therapy was 12.34 ± 20.49 years, GCS 
therapy in the past was applied in 41 patients. All patients received MTX (10 mg or 15 mg weekly) between 2004 and 2013 because 
of chronic progressive pulmonary sarcoidosis. Therapy was planned for 24 months. Patients underwent regular clinical evaluation, 
pulmonary function assessment, exercise ability testing (6MWT), and chest radiography for therapy effectiveness every six months 
and side effects monitoring every 4–6 weeks. Forty-nine patients were included for statistical analysis of treatment efficacy. They 
were retrospectively allocated to “MTX responder” group if an improvement of 10% of FEV1, FVC, TLC, or 15% of DLCO from the 
initial value was documented for at least one parameter or “non-responders” if the patient did not meet the above-mentioned criteria.
Results: Duration of treatment ranged from 6 to 24 months, mean time 60.75 ± 34.1 weeks. For the whole cohort significant 
improvement after MTX therapy was observed for minimal SaO2 (%) (p = 0.043) and for decrease of DSaO2 (%) (p = 0.048) 
in six-minute walk test. The results were significantly better for patients treated with 15 mg than for those treated with 10 mg 
weekly and for those who obtained a greater total amount of MTX during therapy. Significant difference of DLCO%pred was 
observed after six months of MTX therapy between groups treated 15 mg vs 10 mg weekly (73.27 ± 12.7% vs. 63.15 ± 16.4%, 
p = 0.03). Twenty-five patients (55%) met the criteria of “MTX responders” group. Patients who responded well to treatment had 
significantly lower TLC and FVC initial values comparing to “MTX non-responders”. After treatment the only significant difference 
in PFT between groups was noted for DLCO%pred. Eleven patients (22%) stopped the treatment due to adverse events of MTX, 
mild hepatic abnormalities were observed in ten patients (20%), and concomitant infection was found in four patients. There were 
no patients with a fatal outcome.
Anna Goljan-Geremek et al., Methotrexate as a single agent for treating pulmonary sarcoidosis
519www.pneumonologia.viamedica.pl
Conclusions: MTX as a single agent in the treatment of sarcoidosis has proved to be a safe and effective steroid alternative. 
Selected patients with chronic pulmonary sarcoidosis experience definite PFT improvements after MTX treatment. There is need 
to search for predictors of MTX treatment effectiveness.
Key words: methotrexate, sarcoidosis, PFT, treatment
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Streszczenie
Wstęp: Kortykosteroidoterapia jest według aktualnych wytycznych WASOG/ATS/ERS leczeniem pierwszego rzutu u chorych na 
przewlekłą sarkoidozę. Jest to leczenie obarczone wysokim ryzykiem wystąpienia objawów ubocznych, które pogarszają rokowa-
nie odległe. Jednocześnie nie ma pewności, że glikokortykosteroidy (GKS) modyfikują naturalny przebieg choroby. Celem pracy 
była ocena skuteczności i bezpieczeństwa leczenia metotreksatem (MTX) w monoterapii chorych na przewlekłą sarkoidozę płucną.
Materiał i metody: Do leczenia zakwalifikowano 50 chorych na przewlekłą sarkoidozę płuc potwierdzoną badaniem histopatolo-
gicznym, 28M i 22K, w średnim wieku 45,55 ± 8,9 roku, ze średnim czasem trwania choroby do włączenia MTX wynoszącym 
12,34 ± 20,49 roku. W latach 2004–2013 zastosowano u tych chorych MTX w monoterapii, w dawkach 10 mg lub 15 mg 
tygodniowo. Czterdziestu jeden pacjentów było wcześniej leczonych GKS. Wszyscy mieli wykonywane badania laboratoryjne, 
czynnościowe oraz radiologiczne układu oddechowego przed rozpoczęciem leczenia i w trakcie monitorowania skuteczności 
(co 6 miesięcy) oraz bezpieczeństwa terapii (co 4–6 tygodni). Do analizy statystycznej oceniającej skuteczność leczenia włączono 
49 chorych. Na podstawie retrospektywnej analizy wyników badań czynnościowych (FEV1, FVC, TLC, DLCO) wykonanych na za-
kończenie leczenia, w porównaniu z wynikami badań czynności płuc przed podaniem MTX (poprawa o 10% w zakresie FEV1, FVC, 
TLC lub o 15% DLCO), wyodrębniono chorych, u których stwierdzono obiektywną, istotną poprawę wskaźników czynnościowych 
płuc po leczeniu (grupa „z obiektywną poprawą po leczeniu”).
Wyniki: Okres leczenia wynosił od 6 do 24 miesięcy, średnio 60,75 ± 34,1 tygodnia. W całej grupie istotną poprawę po leczeniu 
MTX stwierdzono dla SaO2 min (%) (p = 0,043) oraz dla DSaO2 (%) (p = 0,048) ocenianej w czasie testu 6-minutowego marszu. 
Istotnie lepsze efekty leczenia uzyskano w grupie otrzymującej 15 mg MTX tygodniowo oraz u chorych, którzy otrzymali sumarycz-
nie większą dawkę MTX podczas całej kuracji. Istotną statystycznie różnicę po 6 miesiącach leczenia między grupami leczonymi 
15 mg v. 10 mg tygodniowo stwierdzono dla DLCO% pred (73,27 ± 12,7 v. 63,15 ± 16,4; p = 0,03). Obiektywną poprawę po 
leczeniu stwierdzono u 25 pacjentów (55%). Chorzy, u których stwierdzono obiektywną poprawę po MTX, mieli wyjściowo istotnie 
niższe wartości TLC i FVC w porównaniu z grupą bez poprawy po MTX. Po zakończeniu leczenia jedyną istotnie statystycznie 
różnicę między obiema grupami obserwowano w zakresie DLCO. U 11 chorych (22%) przerwano leczenie z powodu objawów 
ubocznych. Najczęściej obserwowanym objawem ubocznym leczenia był wzrost wskaźników wątrobowych (10 chorych, 20%). 
U 4 osób stwierdzono powikłania infekcyjne. U żadnego chorego nie stwierdzono powikłań zagrażających życiu.
Wnioski: Metotreksat w monoterapii może być bezpieczną i skuteczną alternatywą dla steroidów. U części chorych należy 
spodziewać się obiektywnej poprawy czynności płuc po leczeniu. Wskazane są dalsze badania w poszukiwaniu wskaźników 
prognozujących skuteczność leczenia.
Słowa kluczowe: metotreksat, sarkoidoza, badania czynnościowe płuc, leczenie
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Introduction
Low-dose methotrexate (MTX) therapy has 
been used to treat a variety of chronic inflamma-
tory diseases and has proved to be a cornerstone 
therapy [1–3]. Few studies have discussed the 
efficacy of such treatment in sarcoidosis. Patients 
with symptomatic sarcoidosis are usually treated 
with glucocorticosteroids (GCS). However, the 
GCS therapy is associated with significant adver-
se effects and finally does not alter the natural 
history of the disease [4, 5]. 
Data supporting the use of MTX as a sin-
gle therapy for pulmonary sarcoidosis are very 
limited. In most cases MTX was used as a stero-
id-sparing agent [6–9]. There are case reports in 
literature of patients with symptomatic sarcoido-
sis, being refractory to steroids, and successfully 
treated with low-dose methotrexate without 
severe adverse effects. In most published cases 
extrapulmonary sarcoidosis was the target of 
therapy. These findings suggest that low-dose 
methotrexate therapy may be a useful alternative 
treatment for sarcoidosis although the proper 
use and efficacy of MTX as a single agent remain 
unclear.
Recently published recommendations for 
use of methotrexate in sarcoidosis were based 
on the results of one randomised controlled 
trial (RCT), several observational case series 
(10 case series involving more than 10 patients, 
and 32 case reports involving fewer than 10 pa-
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tients) and expert opinions [10]. According to the 
WASOG Task Force, steroids are the first-line the-
rapy in sarcoidosis [11]. The indications for MTX 
in sarcoidosis consist of its use as a second-line 
treatment option in steroid-refractory cases, in 
the presence of steroid-associated adverse ef-
fects, or as a steroid-sparing agent. As a first-line 
treatment option, MTX is indicated as an MTX/ 
/steroid combination therapy or monotherapy in 
exceptional situations [10]. 
In this context the studies looking into the 
efficacy and safety of MTX as a single agent 
in treating chronic progressive sarcoidosis are 
highly anticipated and valuable. The objective 
of the present study was to evaluate the efficacy 
and safety of monotherapy with MTX in chronic 
pulmonary sarcoidosis patients.
Material and methods
Study design
The study was designed as prospective single- 
-centre cohort project. The aim of the study was 
to assess the effectiveness and safety of MTX, 
given as a single agent for chronic progressive 
pulmonary sarcoidosis. Patients were recruited 
from those seen by the authors for symptomatic, 
chronic sarcoidosis [11] at the Respiratory De-
partment of the National Tuberculosis and Lung 
Diseases Research Institute between January 
2004 and December 2013. MTX was proposed 
to patients who were previously unsuccessfully 
treated by systemic corticosteroids and, as a first 
line therapy, to patients who were not treated by 
GCS due to contraindications for such treatment 
or due to refusal of the steroid therapy because 
of possible adverse effects (AE). The decision to 
begin systemic methotrexate therapy in each case 
was taken collectively by a team of investigators 
(the same clinicians for all of the patients) and 
approved by the Head of the Pulmonary Depart-
ment. All patients gave written informed con-
sent of a protocol approved by the local Ethical 
Committee. 
Patients
Inclusion criteria:
—  adult patients (over 18 years old) of either 
gender, with the diagnosis of sarcoidosis 
confirmed by the biopsy, clinical picture of 
the disease compatible with WASOG/ATS/ 
/ERS criteria [11],
—  documented chronic, progressive stage II or III 
pulmonary sarcoidosis according to WASOG/ 
/ATS/ERS criteria [11, 12],
—  patients with pulmonary indication for sys-
temic treatment and: steroid refractory sarco-
idosis or steroid resistant disease, or presence 
of steroid-associated adverse effects with 
contraindication for steroid therapy or pa-
tient’s wish to start treatment with alternative 
to steroid therapy.
Exclusion criteria:
—  extrapulmonary sarcoidosis that required im-
mediate treatment with oral corticosteroids 
(e.g. cardiac sarcoidosis),
—  patients receiving treatment with corticoste-
roids for some other reason,
—  patients with contraindications for MTX,
—  pregnant, lactating women or those planning 
pregnancy,
—  patients with other specific, poorly controlled 
diseases,
—  patients who did not sign the informed con-
sent form.
The therapeutic decision was based on clini-
cal criteria [11–13]: the presence of disabling or 
distressing symptoms of sarcoidosis (dyspnoea, 
cough, wheezing, chest pain) with decreased exer-
cise tolerance confirmed by six-minute walking 
test (6MWT) and:
—  a 10% or more decline of forced expiratory 
volume in one second (FEV1), forced vital 
capacity (FVC), total lung capacity (TLC), or 
a 15% or more decline of diffusing capacity 
(DLCO) for two consecutive measurements 
prior to enrolment, or severe impairment of 
pulmonary function test (PFT) at the initial 
examination, or
—  the presence of progressive pulmonary, pa-
renchymal disease with signs of pulmonary 
fibrosis, confirmed by chest X-ray (CXR) 
and high-resolution computed tomography 
(HRCT) and documented by retrospective 
analysis of the imaging records by two inde-
pendent radiologists (BB, IB). 
Protocol
The protocol of the study is shown in the 
flow chart (Fig. 1). Prior to the administration of 
MTX (visit 0 — initial evaluation, recruitment) 
all patients were followed-up for at least six 
months with no therapy. At the baseline visit 
(visit 1) medical records were collected for: 
BMI, previous treatment, disease duration — 
from establishing the diagnosis of sarcoidosis 
to the baseline visit. Then the indications for 
the treatment with MTX because of pulmonary 
sarcoidosis were confirmed. Patients received 
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Figure 1. Flow chart study design
methotrexate according to our own protocol. 
The therapy was planned for 24 months. Initial 
standard dose was set at 10 mg per week. In indi-
vidual cases a higher dose of 15 mg weekly was 
proposed, according to the recommendations 
adapted from rheumatic diseases and from sar-
coidosis experts’ opinions [12–14]. Additionally, 
all patients took 5 mg folic acid every day (exc-
luding the day of MTX administration). Toxicity 
of therapy was assessed every 4–6 weeks by the 
treating physician during regular medical visits, 
and additional diagnostic procedures were per-
formed if necessary.
Routine laboratory tests (total blood counts, 
hepatic and renal function tests, electrolytes) 
were taken at recruitment (visit 0), at baseline 
visit-initiation of therapy (visit 1), and during 
observational time to check for MTX adverse 
effects (every 4–6 weeks). All the CT scans that 
were performed at the initiation of treatment 
were reviewed for the presence of fibrosis, bron-
chiectasis, and ground glass opacities. Pulmo-
nary function (PF) was assessed by spirometry, 
plethysmography, and diffusion capacity of the 
lung. Measured parameters were presented as 
percentage of predicted value. The measure-
ments of FEV1, FVC, TLC, DLCO, FEV1/FVC, and 
six-minute walking test (6MWT) were performed 
at recruitment, at baseline visit 1, after six mon-
ths of treatment (visit 2), and at medication with-
drawal. All spirometric and plethysmographic 
measurements were performed using the Jaeger 
Master Screen Body, version 4.65, according to 
ERS/ATS 2005 statement. The exercise capa-
city was measured by 6MWT performed on a 
treadmill. Heart rate (HR), blood pressure (BP), 
and pulse oximetry with maximal (at rest) and 
minimal (during exercise) oxygen saturation 
(SaO2min) were recorded, as well as the wal-
king distance (6MWD) and the dyspnoea Borg 
score before and after exercise. The parameters 
taken into account were as follows: dyspnoea 
Borg score, 6MWD, minimal saturation during 
exercise (SaO2min), and degree of desaturation 
during exercise (DSaO2). 
The involvement of extrapulmonary sites was 
diagnosed according to criteria proposed in the 
ACCESS [15]. The longitudinal and transverse 
dimensions of spleen and liver (right and left lo-
bes) were measured by ultrasound at baseline, at 
visit 1, and at MTX withdrawal. Then the results 
were compared to search for possible toxicity of 
therapy. In patients with abnormal laboratory 
findings at baseline visit, suggesting liver disease, 
hepatic biopsy prior to treatment was performed 
and a gastroenterologist opinion was obtained to 
exclude the contraindications for MTX.
The routine check for latent or active tuber-
culosis (TB) infection in our cohort before star-
ting MTX therapy included tuberculin test, and 
sputum and bronchoalveolar lavage (BAL) fluid 
cultures for acid fast bacilli (AFB) and were re-
peated during observational time in case of signs 
or symptoms of respiratory infection.
All infections were reported as adverse events 
(AE) of MTX, even those that did not require an-
tibiotic treatment.
Materials
At the initial visit (visit 0) 76 patients were 
recruited to the study. At baseline visit (visit 1) 
50 patients met the inclusion criteria and did not 
meet the exclusion criteria and were eligible to re-
ceive MTX therapy. Finally the material consisted 
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Table 1.  Pulmonary function test (PFT) in whole cohort. Significant deterioration of FEV1, FVC, and DLCO between visit 0 
and visit 1 as an indication for MTX therapy is shown
Variable
Mean ± SD
6 months before therapy, 
visit 0
N = 46
Baseline: on MTX initia-
tion, visit 1
N = 49
6-month interim, visit 2*
N = 48
End of treatment**, visit 3
N = 49
DLCO %pred 78.07 ± 17.9a, b, c 66.52 ± 15.6a 66.95 ± 15.8b 67.48 ± 16.9c
TLC % pred 90.28 ± 14.0 84.97 ± 18.2 89.74 ± 18.0 89.65 ± 17.4
FVC %pred 90.67 ± 18.5c 79.16 ± 16.1c 84.46 ± 19.1 85.84 ± 19.2
FEV1 %pred 83.89 ± 20.3b, c 70.39 ± 19.5b 72.87 ± 20.6c 73.45 ± 21.0
Post-hoc Tukey’s RIR test, p significance: a< 0.005, b< 0.01, c< 0.05; abbreviations in the text
*in one patient the PFTs were performed in a different Pathophysiological Department, not included in the statistical analysis; **all patients were included, independently 
of treatment duration 
of 28 men (57%) and 22 women (43%) in the age 
range 35 to 62 years. For the statistical analysis 
49 patients were included (one patient was not 
included due to non-compliance). The median 
disease duration, from establishing the diagnosis 
to starting MTX therapy, was 12.34 years (range 
from 1 year to 26 years).
Sarcoidosis in stage II was diagnosed in 28 
patients, and 22 were in stage III. In all cases sar-
coidosis was proven by histological examination. 
All patients had signs of fibrosis confirmed by 
lung HRCT scans. In 17 patients (37%) bronchiec-
tases were present as a consequence of advanced 
fibrosing process in the lungs. In eight patients 
(18%) ground glass opacities were described in 
lung CT scans.
Extrathoracic sarcoidosis was diagnosed in 
37 patients (74%): spleen involvement was ob-
served in 19 cases, lymph nodes involvement in 
18 cases, skin in 10 cases, and hepatic sarcoido-
sis in 9 cases. Liver biopsy was performed in 12 
cases, and 8 cases revealed sarcoid granulomas. 
One case of HCV infection was diagnosed and the 
patient received an MTX regimen of 10 mg weekly 
after gastroenterologist approval. 
In 41 cases (82%) MTX was administered to 
patients who were previously treated by systemic 
corticosteroids because of progressive pulmonary 
sarcoidosis. Twenty patients received one course 
of GCS treatment (two years of therapy), 21 pa-
tients received more than one course (total dura-
tion of GCS therapy > 2 years) and were refractory 
after GCS withdrawal. MTX was proposed to 17 
patients who did not experience any significant 
improvement after GCS, and to 24 patients who 
were responsive to GCS but experienced unaccep-
table AE after GCS therapy (N = 10) or refused 
to be treated with GCS again (N = 14). The mean 
time between the end of GCS therapy and institu-
tion of MTX therapy was 18.6 ± 18.3 months (ran-
ge 6–85 months). In nine cases MTX (18%) was 
proposed as a first-line therapy in patients who 
refused the steroid therapy because of potential 
AE (N = 5; 10%) or because of contraindication 
for such treatment (N = 4; 8%). Before starting 
the MTX therapy, significant deterioration in PFT 
was observed in 41 patients (82%). In 5 (10%) 
patients the initial PFTs were abnormal (at visit 
0), with no changes during six months of observa-
tion before starting MTX therapy, but radiological 
progression was observed between visit 0 and 
visit 1, accompanied by disabling (according to 
subjective patients’ opinion), symptoms. The PFT 
results at different time intervals, showing the 
significant function deterioration that justified 
the indications for MTX therapy, are represented 
in Table 1 and Figure 2.
Evaluation of effectiveness of therapy
Patients were classified after treatment as 
“responders” and “non-responders” to MTX, 
based on four measures of PFT (FEV1, FVC, TLC, 
DLCO) and CXR. Additionally, 6MWT parame-
ters (Sa02min, DSa02, and dyspnoea level) were 
assessed. A 10% improvement of FEV1, or FVC, or 
TLC or 15% of DLCO from the initial value (before 
treatment) compared to values at the time of MTX 
termination for at least one parameter classified 
a patient as an “MTX responder”. Patients with 
deterioration of PFT parameters superior to 10% 
in FEV1, FVC, TLC or 15% of DLCO, and those 
who had no changes in the PFT parameters during 
treatment, were classified as “MTX non-respon-
ders”. First analysis of effectiveness was made 
at the visit occurring six months (visit 2) after 
initiation of therapy as it was proven by other 
authors that one can expect the MTX effectiveness 
by six months of treatment [7, 8, 16].
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Figure 2. The comparison of pulmonary function test (PFT) in whole cohort,  starting from the recruitment (visit 0), than baseline (visit 1), after 6 months of the-
rapy (visit 2) and at the MTX withdrawal. Significant deterioration of FEV1, FVC, DLCO between visit 0 and visit 1 as an indication for MTX therapy is shown
In the absence of deterioration or unaccepta-
ble side effects, patients continued receiving the-
rapy with MTX, with the intention of maintaining 
treatment for 24 months. Reassessment of efficacy 
of MTX was performed every six months. The 
therapy was terminated prematurely (before the 
planned 24 months) in patients who developed 
adverse effects related to MTX therapy, reported 
subjective intolerance of therapy, presented wor-
sening of symptoms, or deterioration of PFT or 
radiological picture due to sarcoidosis on MTX 
treatment. It was also terminated if the patient 
had shown no evidence of improvement and 
remained consistently stable for two consecutive 
visits (Fig. 3). To determine the number of patients 
responsive to therapy all cases were included, 
independently of the duration of treatment.
Statistical analysis
Statistical analyses were performed using 
Statistica 10 software (StatSoft, Inc., USA, 2011) 
and MedCalc Statistical Software version 13.3.1 
(MedCalc Software bvba, Ostend, Belgium, 2014). 
Tests were considered significant when p < 0.05. 
Data distribution was analysed using the Kolmo-
gorov-Smirnov test with Lilliefors correction. 
Quantitative data were described using mean ± 
SD. If a variable demonstrated normal distribu-
tion and homogenous variance, t test was applied. 
Between-group characteristics were described 
using t tests for paired or independent variables. 
For nonparametric data comparisons between 
groups Mann-Whitney U test was used for inde-
pendent samples and Wilcoxon test for paired 
samples. Categorised, qualitative, between-group 
analyses were performed using the Pearson c2 test 
with appropriate corrections for N. 
Results
Thirty-one (66%) patients received MTX at 
dose of 10 mg weekly and 18 (36%) patients at 15 mg 
weekly (Table 2). In the group treated with 10 mg 
weekly, 18 patients (54%) were classified to the 
“non-responders” group. In the group treated 
with 15 mg weekly, only six patients (35%) were 
classified as “non-responders”. In the group of 
patients treated with 15 mg weekly, 7/18 (39%) 
patients completed 24 months regiment (vs. 7/31, 
22%, patients from the 10 mg-weekly group). 
Patients treated with 15 mg weekly had signifi-
cantly more important amelioration (of > 10%) 
of DLCO compared to patients receiving 10 mg 
weekly (Tab. 2).
The mean duration of therapy for the whole 
group was 60.74 ± 34.1 weeks. Fourteen patients 
(28%) completed the 24-month MTX treatment. 
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Figure 3. Study flow of patients who received methotrexate (MTX) during  2 year follow up from start of treatment. 49 patients are still in follow up.
Table 2.  The dose-related (10 mg vs. 15 mg weekly) effect of methotrexate (MTX) therapy on pulmonary function test 
(PFT) measured at baseline (1), after 6 months of therapy (2) and at termination of MTX (3). A significant improve-
ment of 10% was observed between groups (10 mg vs. 15 mg weekly) for DLCO after six months of MTX therapy
Variable
10 mg weekly (N = 31) 15 mg weekly (N = 18)
p
Mean ± SD Mean ± SD
(1)DLCO %pred 65.48 16.2 68.38 14.6 NS
(1)TLC % pred 86.00 15.7 83.14 22.2 NS
(1)FVC %pred 79.30 16.7 78.91 15.5 NS
(1)FEV1 %pred 71.98 20.8 67.57 17.3 NS
(2)DLCO %pred 63.15 16.4 73.27 12.7 0,030
(2)TLC % pred 88.67 16.4 91.52 20.8 NS
(2)FVC %pred 82.31 21.1 88.04 15.0 NS
(2)FEV1 %pred 73.09 22.4 72.49 17.5 NS
(3)DLCO %pred 64.63 17.1 74.25 16.5 NS
(3)TLC % pred 88.54 14.9 91.57 21.3 NS
(3)FVC %pred 83.07 20.6 89.88 15.2 NS
(3)FEV1 %pred 73.7 22.2 72.92 19.4 NS
MTX responders 13 (46%) 12 (65%)
MTX non-responders 18 (54%) 6 (35%)
Sixteen patients (32%) terminated the MTX 
therapy after six months for various reasons: 
subjective intolerance (N = 2), adverse effects of 
MTX therapy (N = 3), no improvement in any of 
analysed clinical parameters (N = 5), or progres-
sion of sarcoidosis on treatment (N = 6). Nine-
teen patients (38%) were treated for longer than 
six months but did not complete the 24-month 
protocol because of the following: stabilisation 
of sarcoidosis for two consecutive control visits 
(N = 13), adverse effects or subjective intole-
rance (N = 6). One patient was excluded from 
the study after six months of therapy because 
of non-compliance. For the further statistical 
analysis of treatment effectiveness 49 patients 
were included (Fig. 3)
Anna Goljan-Geremek et al., Methotrexate as a single agent for treating pulmonary sarcoidosis
525www.pneumonologia.viamedica.pl
Baseline characteristics of the treatment 
cohort (49 patients) according to the response to 
MTX are presented in Table 3. Looking for the 
impact of MTX on different clinical indices in 
the whole cohort, a significant improvement was 
observed for minimal SaO2 (%) measured during 
exercise (p = 0.043) and for DSaO2 (%) (p = 0.048) 
(Tab. 3). During the MTX treatment of the whole 
cohort no significant increase of any of analysed 
PFT parameters was observed (Tab. 3, Fig. 2).
Patients with objective benefits from therapy 
(“MTX responders” group) received significantly 
higher total dose of MTX (919.6 ± 376 mg vs. 
512.5 ± 380 mg, p = 0.0004) and were treated lon-
ger (76.8 ± 30.6 weeks vs. 44.04 ± 29.7 weeks, p = 
0.001) (Tab. 4). They also had significantly lower 
TLC and FVC initial values compared to “MTX 
non-responders” (Tab. 4). Other mean initial PFT 
values were also lower in the “MTX responders” 
group compared to the “MTX non-responders” 
group although the difference did not reach the 
statistical significance. No other significant dif-
ferences between groups (“MTX responders” vs. 
“MTX non-responders”) were observed in any of 
analysed baseline parameters (Tab. 4), including 
previous GCS therapy. 
Radiological improvement after MTX therapy 
was revealed in 28 (56%) patients. In all those 
cases partial regression of disseminated changes 
were observed, without impact on radiological 
signs of fibrosis. In three cases radiological im-
provement was not associated with significant 
functional amelioration. In all patients with 
significant improvement in at least one PFT para-
meter a radiological improvement of CXR/lungCT 
was observed. No normalisation of radiological 
picture was observed in any case. 
All patients with extrathoracic sarcoidosis 
who responded to MTX therapy (by the signifi-
cant improvement in PFT) experienced partial 
or total extra thoracic lesion reduction. The 
most sensitive to MTX therapy were skin lesions 
(> 50% reduction from baseline changes).
In one patient with advanced systemic lymph 
nodes sarcoidosis that accompanied pulmonary 
lesions the progression of extrathoracic sarcoido-
sis during MTX treatment led to premature MTX 
withdrawal.
In 17 patients (34%) GCS treatment follo-
wing MTX withdrawal was necessary because of 
disabling disease. In all those cases sarcoidosis 
improved on steroids during the six months of 
follow-up.
In the “MTX responders” group FVC%pred 
and TLC%pred measured after therapy reached 
the values within the normal range (respectively: 
FVC%pred: 73.6 ± 12.8 before treatment vs. 89.1 
± 17.6 after treatment, p < 0.0001 and TLC%pred: 
77.9 ± 12.7 before treatment vs. 87.9 ± 13.4 after 
treatment, p < 0.0001) (Tab. 5).
Table 3. Characteristics of lung function and exercise performance before and after MTX treatment in whole cohort
Variable Baseline values(N = 49/50 — one patient not included) 
After treatment
(N = 49/50) p
DLCO [mmol/min/kPa] 6.38 ± 1.8 6.54 ± 2.2 0.70 NS
DLCO (%pred) 66.52 ± 15.6 67.48 ± 16.9 0.77 NS
TLC (L) 5.15 ± 1.1 5.43 ± 1.2 0.21 NS
TLC (%pred) 84.97 ± 18.2 89.65 ± 17.4 0.19 NS
FVC (L) 3.35 ± 0.9 3.52 ± 1.05 0.39 NS
FVC (%pred) 79.16 ± 16.1 85.84 ± 19.2 0.063 NS
FEV1 (L) 2.42 ± 0.8 2.47 ± 0.8 0.75 NS
FEV1 (%pred) 70.39 ± 19.5 73.45 ± 21.0 0.45 NS
FEV1%FVC 0.77 ± 11.8 0.68 ± 12.5 0.34 NS
SaO2 min (%) 91.0 ± 3.8 92.38 ± 3.6 0.043
DSaO2 (%) 5.27 ± 3.2 4.09 ± 2.9 0.048
Distance [m] 531 ± 106 546 ± 106 0.33 NS
Distance (%pred) 87.20 ± 11.0 92.3 ± 11.6 0.12 NS
Exercise dyspnoea (Borg score, points) 1.22 ± 1.9 0.75 ± 1.3 0.35 NS
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Table 4.  Baseline characteristics of treatment cohort in relation to treatment effectiveness (responders vs. non-respon-
ders to methotrexate)
Variable
Mean ± SD
All patients
(N = 49)
MTX responders
(N = 25)
MTX non-responders
(N = 24) P value
Age at start of therapy (yrs) 45.55 ± 8.9 45.76 ± 8.9 45.33 ± 9.0 0.87 NS
Male sex, N (%) 28 (57.1) 16 (64.0) 12 (50.0) 0.55 NS
BMI [kg/m2] 27.60 ± 4.5 27.86 ± 4.8 27.29 ± 4.2 0.67 NS
MTX total dose [mg] 720.20 ± 427 919.60 ± 376 512.50 ± 380 0.0004
Dose/BMI [mg/kg/m2] 27.33 ± 16.2 34.06 ± 15.3 19.33 ± 13.7 0.0009
Duration of treatment (weeks) 60.75 ± 34.1 76.80 ± 30.6 44.04 ± 29.7 0.001
Smoking
Current, N (%) 2 (4.35) 0 (0) 2 (9.09) 0.21 NS
Former, N (%) 23 (50.0) 11 (45.83) 12 (54.55) 0.21 NS
Disease duration 12.34 ± 20.49 12.14 ± 21.1 12.56 ± 20.3 0.91 NS
Bronchiectases, N (%) 17 (38.64) 9 (42.86) 8 (34.78) 0.58 NS
Ground glass opacities, N (%) 8 (17.78) 3 (13.64) 5 (21.74) 0.48 NS
Previous prednisone therapy, N (%) 41 (82) 21 (80.00) 20 (79.17) 0.94 NS
PFT (%pred)
FEV1 70.39 ± 19.5 66.26 ± 16.4 73.14 ± 21.1 0.702 NS
FVC 79.16 ± 16.1 73.65 ± 12.8 83.42 ± 16.7 0.025
TLC 84.97 ± 18.2 77.95 ± 12.7 91.61 ± 20.6 0.007
DLCO 66.52 ± 15.6 64.37 ± 14.8 67.63 ± 15.8 0.46 NS
FEV1%FVC 77 ± 11.8 71.99 ± 11.4 69.92 ± 12.5 0.53 NS
Airflow limitation, N (%) 18 (36.7) 9 (36.0) 9 (37.5) 0.91 NS
6MWT
SaO2 min (%) 91 ± 3.8 91.2 ± 3.0 90.6 ± 4.5 0.86 NS
DSaO2 (%) 5.27 ± 3.2 5.21 ± 3.0 5.52 ± 3.4 0.81 NS
Distance [m] 531 ± 106 570.7 ± 91 525.2 ± 118 0.93 NS
Dyspnoea (Borg score, points)
Before exercise 0.11 ± 0.43 0.21 ± 0.59 0.00 ± 0.0 0.469 NS
After exercise 1.22 ± 1.9 1.56 ± 2.12 0.91 ± 1.64 0.463 NS
Extrapulmonary involvement, N (%) 36 (73.47) 17 (68.00) 19 (79.17) 0.37 NS
Skin, N (%) 10 (20.41) 4 (16.00) 6 (25.00) 0.43 NS
Lymph nodes, N (%) 18 (37.50) 8 (32.00) 10 (43.48) 0.41 NS
Liver, N (%) 9 (19.55) 4 (16.00) 5 (22.73) 0.55 NS
Spleen, N (%) 19 (38.78) 12 (48.00) 7 (29.17) 0.17 NS
Others, N (%) 7 (14.29) 2 (8.00) 5 (20.83) 0.20 NS
Multiple (at least 2 organs) involvement, 
N (%)
21 (42.86) 8 (32.00) 13 (54.17) 0.11 NS
In the “MTX non-responders” group the 
most significant deterioration from baseline 
values during the treatment were observed for 
DLCO%pred (67.6 ± 15.8 vs. 61.1 ± 16.4, p = 
0.003) and FEV1%pred (73.1 ± 21.1 vs. 68.8 ± 
21.6, p = 0.022) (Fig. 4).
After treatment the only significant difference 
in PFT between groups was noted for DLCO. Dif-
fusing capacity was significantly higher in “MTX 
responders” vs. “MTX non-responders” (Tab. 5).
From the total group of 50 patients, 11 (22%) 
stopped the treatment because of adverse effects 
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Table 5.  The results of pulmonary function test before and after methotrexate treatment, in relation to treatment effecti-
veness (responders vs. non-responders to methotrexate)
Variable
Mean ± SD
MTX responders
(N = 25)
MTX non-responders
(N = 24)
Before treatment After treatment Before treatment After treatment
FEV1 (% pred) 66.26 ± 16.4 78.15 ± 19.7 73.14 ± 21.1 68.75 ± 21.6
FVC (% pred) 73.65 ± 12.8* 89.08 ± 17.6 83.42 ± 16.7* 81.92 ± 19.8
TLC (% pred) 77.95 ± 12.7** 87.88 ± 13.4 91.61 ± 20.6** 91.50 ± 20.9
DLCO (% pred) 64.37 ± 14.8 74.93 ± 15.8*** 67.63 ± 15.8 61.12 ± 16.4***
FEV1%FVC 71.99 ± 11.4 69.80 ± 9.5 69.92 ± 12.5 67.59 ± 15.0
Significant differences between groups were found for FVC and TLC before treatment (*p = 0.025, **p = 0.007) and for DLCO after treatment (***p = 0.0042)
of MTX. Gastrointestinal (GI) problems (nausea, 
stomachache) and malaise, without any labora-
tory abnormalities, were reported by five patients 
and occurred most often within the first three 
months of therapy leading to withdrawal in two 
cases. The most frequently reported side effects 
were mild hepatic abnormalities (in 10 patients, 
20%). In those cases, none of important organ 
dysfunction due to therapy was diagnosed. Four 
patients had to quit therapy because of the eleva-
tion of hepatic enzymes or bilirubin. In one case 
hepatic abnormalities were associated with mild 
leukopenia (after 15 months of treatment) and in 
one case with infection of varicella zoster (patient 
quit MTX treatment after five months of therapy). 
None of the patients experienced severe hepatic 
function decline, and liver function recovered in 
all patients after therapy discontinuation.
In patients with hepatic sarcoidosis confirmed 
with liver biopsy, no significant laboratory changes 
in hepatic function were observed during treatment.
No important anaemia or other haematologi-
cal disorders were noticed in our cohort.
Infections were reported in four cases (8%) 
(including one case that was associated with he-
patic abnormalities) and were the reason to resign 
from treatment. In two cases tuberculosis was 
confirmed with positive cultures. In those two 
cases the radiological progression of disseminated 
changes were diagnosed during MTX treatment, 
and patients underwent all diagnostic procedures 
to elucidate the nature of deterioration of CXR. 
In one case a suspicion of pulmonary tumour ne-
cessitated verification with an open lung biopsy, 
which showed tuberculoma. In the second case 
the BAL fluid cultures were BK positive. Patients 
completed the six-month antituberculosis (an-
ti-TB) regimen. During this anti-TB treatment 
important radiological and functional progression 
of sarcoidosis was observed.
One patient was admitted to hospital after 
three months of therapy because of severe dysp-
noea, cough, and hypoxaemia. His CXR was simi-
lar to baseline, with no radiological progression of 
disseminated changes or fibrosis on chest HRCT 
scans. His serology was positive for Mycoplasma 
and Chlamydia antibodies. MTX therapy was 
stopped and the patient received antibiotics, ste-
roids, and oxygen therapy and recovered within 
two weeks. Steroids were continued for his pul-
monary sarcoidosis with significant improvement 
in six months of follow up.
In two patients, during the routine sputum 
check, Aspergillus fumigatus colonies were found 
with no signs or symptoms of allergic or systemic, 
invasive aspergillosis. In those patients the reason 
for discontinuation for treatment was lack of effi-
cacy of MTX. There were no patients with a fatal 
outcome while receiving MTX therapy.
For the whole group no significant differences 
were observed before and after treatment in the 
majority of safety parameters. The only significant 
differences between the initial and post-treatment 
values were noticed for alanine aminotransferase 
(ALT), but the mean ALT value after therapy for 
the whole cohort (33.96 ± 25.74 U/L, p = 0.043) 
was within normal values.
Discussion
This was an prospective single-centre real-li-
fe open label study of methotrexate as a monothe-
rapy in chronic, progressive pulmonary sarcoido-
sis. Most patients had been treated previously 
with GCS, without maintained improvement or 
with important adverse effects. In our study the 
treatment with MTX showed objective pulmonary 
benefits in 55% of the treated cohort. The disease 
duration before initiating MTX therapy, high rate 
of extrapulmonary sarcoidosis, PFT deterioration 
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Figure 4. Individual results of MTX treatment on PFT parameters in “Responder” and “Non-responder” groups
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before enrolment and previous steroid treatment 
confirm that our cohort comprised patients with 
chronic and disabling sarcoidosis. Statistical 
analysis of PFT results comparing the initial vi-
sit values to baseline values showed significant 
deterioration of FEV1, FVC, and DLCO. This may 
reflect the active inflammatory process and justify 
the indication for therapy. 
We observed a dose-related effect of MTX in 
our cohort. MTX total dose was almost double 
in the “MTX responders” group compared to the 
“non-responders” group, and that was confirmed 
by adjustment to the BMI. Our study protocol 
allowed MTX therapy to be started with either 
dose of 10 mg or 15 mg weekly, without any 
precise criteria justifying this decision, besides 
clinical evaluation. This is a weak point of the 
study and makes the interpretation of the dose 
relation effectiveness very difficult. The MTX 
dose of 10 mg per week was adapted from a 
randomised controlled study showing that sarco-
idosis patients without previous treatment, who 
took MTX 10 mg weekly, required significantly 
lower doses of glucocorticosteroids than patients 
taking placebo [7]. In this study MTX was given 
as a steroid-sparing agent. We presumed that in 
individual situations (e.g. obesity, need for high 
dose of steroids in the past to control the disease) 
MTX given as a monotherapy should be admi-
nistered in a higher dose. There are no studies 
comparing higher and lower dosages of MTX to 
provide the best treatment effect with acceptable 
safety profile in sarcoidosis, but the dose-depen-
dent efficacy was proven in rheumatoid arthritis 
patients [17, 18]. Our treatment protocol was ada-
pted from recommendations for the use of MTX 
in rheumatic disorders and supplemented with 
expert opinions [8, 12, 13]. Recently published 
multinational recommendations for the use of 
MTX in sarcoidosis suggest that an initial dose 
of oral MTX between 5–15 mg weekly, without 
indicating potential candidates for the dose of 15 
mg [10]. The escalation of initial dose to 10–15 
mg per week may be considered after eight weeks 
in cases presenting insufficient response and 
acceptable safety profile.
The choice of the treatment dose in our pro-
tocol was based on physicians’ experience and 
was adapted to individual patients. The risks and 
benefits of higher dose of MTX were explained to 
the patient before the final decision was made. 
In our study 34% of patients agreed to be treated 
with the dose of 15 mg weekly. In this group we 
observed significantly higher rate of 24-month 
treatment achievement, a higher rate of “MTX 
responders” patients, and a lower rate of patients 
who stopped the therapy after six months. All 
the infections that led to premature termination 
of therapy were diagnosed in individuals treated 
with 10 mg weekly. It seems that MTX dose of 
15 mg weekly is safe and might be more effective 
than 10 mg weekly, independently of BMI.
The length of therapy was significantly longer 
in “MTX responders” vs. “non-responders”. This 
might be explicable by the treatment protocol, 
according to which the MTX therapy was termi-
nated before the planned 24 months because of 
very different reasons (e.g. stabilisation of the 
disease documented by two consecutive visits, 
side effects, subjective wish of the patient). By 
the end of therapy we did not know who met 
the criteria of the “MTX responders” group. The 
statistical analysis was performed retrospectively 
to determine patients who had objective response 
to MTX therapy. PFT results seemed to be the 
most valuable outcome parameters for pulmonary 
sarcoidosis. The lack of a precise end-point for 
therapy, which would allow a reliable conclusion 
to be drawn about the relation between dose and 
treatment duration and clinical effect of therapy, is 
a weak part of the study protocol. In some patients 
the clinical effect of the therapy might be reached 
earlier, and some patients may need to be treated 
longer to achieve the clinical improvement. This 
is a point that needs further exploration.
The monotherapy with MTX should be con-
sidered from different aspects: the indications for 
therapy, the effectiveness, and the safety.
The decision to treat sarcoid patients is 
usually difficult. In most cases the disease can 
resolve spontaneously or become self-limited. 
In those situations the pharmacotherapy might 
cause adverse effects that would not be balanced 
by the benefit from the treatment [12, 13, 19, 20].
The prognostic parameters and predictors of 
remission in sarcoidosis are not evident, espe-
cially for the disease that lasts over two years. 
The potential group of patients with pulmonary 
sarcoidosis that could benefit from medication 
is not defined. Therefore, there is no precise 
evidence about who should be treated [21, 22]. 
In order to minimise the confounding issue of 
spontaneous remission, in our study protocol 
patients demonstrating progressive radiological 
and/or physiological changes were eligible, ac-
cording to the definition of chronic pulmonary 
sarcoidosis adapted from WASOG Task Force and 
experts’ opinions [11, 12].
Most physicians involved in care of sarcoid 
patients admit that patients with disabling symp-
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tomatic disease, prolonged course, and evidence 
of progressive functional damage of affected 
organs are potential candidates for pharmacothe-
rapy. Moderate-to-severe dyspnoea at presenta-
tion is an independent predictor of the need for 
systemic therapy for more than two years after 
diagnosis [23]. The presence of pulmonary fibro-
sis is associated with chronic disease and worse 
clinical outcome [24]. Defining chronic progres-
sive sarcoidosis on the basis of PFT deterioration, 
exercise capacity reduction, and progression of 
radiological changes [11–13] means that the tre-
ated group will always be heterogeneous. In the 
study protocol we did not include any laboratory 
criteria for diagnosing active disease; however, 
we believe that it is important to do so in the 
future. We are convinced that the indications 
for treatment should include the assessment of 
disease activity, based also on assessment other 
than radiological and/or functional. 
An absolute indication for treatment includes 
the manifestations of the disease that are life 
or organ threatening. About 20–25% of sarcoid 
patients will have a permanent decrease in lung 
function, about 10% will develop pulmonary 
fibrosis, and 5–10% of patients will die from 
respiratory failure or cor pulmonale [25–27]. 
Glucocorticosteroids are considered the first-line 
treatment, but this is an imperfect solution. This 
is a potentially toxic therapy with a high rate 
of adverse effects. It influences the long-term 
prognosis in individual patients and may impair 
quality of life, more than the disease itself, espe-
cially in young people. In some patients GCS are 
contraindicated even in a severe case of sarco-
idosis because of possible complications. What is 
more, this treatment does not cure the sarcoidosis, 
so one can expect recurrence of disease with drug 
withdrawal. The next issue are refractory cases 
who need other treatment solutions.
A systematic literature search shows that 
randomised controlled trials (RCT) supporting 
the use of MTX in sarcoidosis are very limited 
[10, 13]. There is a lack of controlled studies 
comparing the efficacy and safety of GCS treat-
ment vs. MTX monotherapy. It is more than likely 
that no ethics board would approve such a study 
while GCS therapy is recommended by experts’ 
guidelines WASOG/ERS/ATS as a first-line tre-
atment in sarcoidosis [11]. On the other hand, 
in rheumatoid arthritis (RA) and other systemic 
immune mediated disorders, MTX has proven, 
from several RCTs and high-quality cohort stu-
dies, to be the best therapeutic option to modify 
the natural course of the disease [2, 14, 28, 29]. 
In those diseases GCS was the first-line treatment 
in the past. It has to be proven that MTX is a safe 
and efficient treatment option before considering 
it as a first-line therapy for sarcoidosis. 
As well as in other diseases (i.e. juvenile 
rheumatoid arthritis, asthma), there were “respon-
ders” and “non- responders” to low-dose MTX 
[30, 31]. The decision to qualify the patient to the 
“responders” vs. “non-responders” group based 
on the PFT assessment was made retrospectively, 
with the intention of searching for an objective 
measure of efficacy. Progressive pulmonary sar-
coidosis was the indication for MTX treatment in 
our cohort, so the PFT assessment at the end of 
therapy seemed to be the most logical, credible, 
objective outcome parameter.
In this first analysis of collected data we fo-
cused on the impact of MTX treatment on lung 
function, independently of the radiological pictu-
re. The lack of a recognised radiological objective 
method that would allow for the comparative 
study of the radiological picture before and after 
treatment makes the objective quantification of 
radiological changes very difficult. For extrapul-
monary sarcoidosis we acknowledge that there 
is no standardised or validated assessment of 
treatment response. MTX therapy in previously 
published case reports was indicated mostly for 
extrapulmonary sarcoidosis [7–9]. The heteroge-
neity of the treatment group makes the clinical 
evaluation of effectiveness of therapy very dif-
ficult. Some patients left the study because of 
subjective intolerance after six months of therapy. 
We have observed that some patients improved 
within six months and remained stable for the 
further months of treatment while others needed 
more than six months of therapy to experience 
an improvement. This explains why some indivi-
duals were treated for more than six months but 
stopped therapy before the scheduled 24-month 
protocol. In two cases, after the initial PFT im-
provement, infectious complications developed 
during the observational time and led to prema-
ture discontinuation of therapy. The PFT results 
deteriorated because of concomitant infection, 
not because of lack of efficacy of treatment, but 
the patients were classified as “non-responder”. 
In our cohort 55% of patients experienced 
a significant improvement in at least one of PFT 
parameter (FEV1, FVC, TLC, or DLCO). This be-
neficial effect of MTX therapy on lung function 
was already confirmed in previous studies, even 
in patients who were treated because of extra-
pulmonary indications [7–9, 32]. A comparison 
of the PFT parameters in our cohort before and 
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after treatment revealed the significant amelio-
ration of each analysed parameter in the “MTX 
responders” group.
Patients who benefited from MTX therapy 
were those with initially impaired volume and 
capacity parameters. Patients who responded 
well to treatment had significantly lower TLC 
and FVC initial values compared to “MTX non
-responders”. The “complete response” was seen 
only for FVC and TLC, and the most “sensitive” 
parameter for therapy was FVC.
Additionally, DLCO value after treatment 
in the groups of “MTX responders” vs. “non-re-
sponders” was shown to be significantly higher 
in the “MTX responders” group. It has been 
proven that MTX shows an anti-inflammatory 
effect, suppressing alveolar macrophage cytoki-
ne release and lymphocytic alveolitis [33]. The 
DLCO improvement after treatment may reflect 
an anti-inflammatory activity of MTX if we look 
at the DLCO impairment as an indirect sign of 
alveolar inflammation [34].
A similar impact of MTX therapy on PFT 
parameters was noted by Vorselaars [9]. The 
authors observed an improvement (> 10%) of at 
least one of the parameters (FEV1, VC, and DLCO) 
in 57% of patients, independently of treatment 
indications (patients received the steroid-sparing 
therapy MTX or azathioprine because of pulmo-
nary or extrapulmonary indication) and with no 
significant differences between azathioprine and 
methotrexate groups (145 patients received MTX 
as a steroid sparing agent). The important diffe-
rence between our study group and Vorselaars 
cohort is that in our group MTX was the single 
agent in all 49 patients while in Vorselaars cohort 
only 13 patients out of 200 received MTX as 
a monotherapy. 
Other authors have reported sarcoidosis im-
provement in 66% of patients treated with MTX. 
Lower and Baughman used methotrexate (10 mg 
weekly) as a steroid-sparing agent for over two 
years in 50 patients with intrathoracic sarcoido-
sis. They observed a > 10% of VC improvement 
in 22 cases (vs. 28 non-responders) [8]. The im-
provement of PFT in the Vorselaars [9] and Lower 
[8] cohort might be attributable to combined the-
rapy. The authors did not compare the effects of 
treatment in groups receiving MTX monotherapy 
vs. MTX combined with steroid therapy.
Until now, no study has focused on impact 
of MTX therapy on exercise tolerance. Baughman 
looked at the Borg dyspnoea scale during exercise 
and noticed an insignificant decrease for the MTX 
group. In that study, MTX was a steroid-sparing 
agent that was compared to placebo and proved to 
be effective in reducing the prednisone dosage [7]. 
In interstitial lung diseases 6MWT has pro-
ven to be a useful, reliable tool for both predicting 
mortality and monitoring response to therapy. 
In the Baughman study on 6MWT in sarcoidosis 
the walk distance depended on FVC and mini-
mal oxygen saturation [35]. Although the MTX 
therapy had no impact on the 6MWT distance in 
our cohort, one may expect a positive influence of 
treatment on the exercise ability in a larger group 
of sarcoid patients with improvement of FVC 
and minimal oxygen saturation after treatment. 
Both were shown to improve in our patients after 
MTX therapy. The assessment of 6MWT in our 
studied group revealed a significant improvement 
in objective parameters: the minimal SaO2 during 
exercise significantly improved, and the degree of 
desaturation during exercise significantly decre-
ased after treatment for the whole group. Those 
parameters seem to change independently of PFT 
indices because we did not find any significant 
differences in exercise ability indices between 
the “MTX responders” and the “MTX non-re-
sponders” group. We suppose that MTX might 
improve the exercise ability by its influence also 
on parameters other than FVC, which has been 
proven to be equally important. Baughman and 
Lower concluded from their study on 6MWT in 
sarcoidosis that 6MW distance depends on mul-
tiple factors, not only pulmonary function [35]. 
We did not observe any significant impact of MTX 
therapy on Borg dyspnoea scale or on 6MWT 
distance for the whole group, even if comparing 
“MTX responders” vs. “MTX non-responders” 
before and after treatment.
When comparing the PFT results at diffe-
rent study control visits between patients who 
received the “first-line MTX therapy” to those 
treated by GCS in the past, we did not find any 
significant differences at recruitment, baseline, 
and during MTX therapy. No conclusions can be 
drawn from this analysis because the group of 
“first-line” MTX treatment was relatively small.
MTX therapy was shown to be safe in our co-
hort. Only in two cases, the subjective intolerance 
led to premature MTX withdrawal. A total of 11 
patients (22%) stopped the therapy because of 
AE. One patient experienced varicella zoster and 
quit MTX treatment after five months of therapy.
This dropout is similar to that described by 
Vorselaars (37 patients, 18.5%) and the Higher to 
Lower study (9.5%) and to the Vucinic study (no 
one had to stop MTX therapy because of AE in 
six months of treatment) [8, 9, 32].
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The problems of interpretation of abnormal 
laboratory findings in sarcoidosis arise from diffi-
culties in separating the drug-related suppressive 
effects on the bone marrow or hepatic function 
and those caused by the disease.
Serial studies of patients with sarcoidosis 
have shown that lymphopaenia is the most com-
mon abnormality, significant anaemia is seen in 
20% of cases, and leukopaenia occurs in 10% of 
cases. Those abnormalities are the result of the 
presence of bone marrow granulomas or toxic 
effects of different cytokine release in active 
sarcoidosis [36]. We observed only one case of 
leukopaenia that led to MTX discontinuation with 
no important reduction of neutrophil count. The 
low incidence of haematological side effects in 
our cohort might be partially attributable to the 
fact that the MTX treatment was applied just in 
patients with normal total blood count and no 
evidence of marrow disruption. Moreover, folic 
acid administration was higher (5 mg daily) com-
pared to other studies [7–9].
Liver toxicity from MTX in sarcoidosis is not 
easily predicted on the basis of any liver function 
tests [37, 38]. The presence of liver disease due to 
sarcoidosis is not a contraindication to treatment 
with MTX. In some cases with liver involvement 
from sarcoidosis, MTX therapy can improve 
the liver function tests. One of the appreciated 
guidelines is to re-evaluate patients with liver 
biopsy after each gram of cumulative therapy if 
the continuation with MTX is recommended [37].
In our study we decided to perform the liver 
biopsy before MTX treatment to determine the defi-
nitive diagnosis of hepatic abnormalities [39]. In one 
patient hepatitis C (HCV) infection was discovered. 
He received a regimen with 10 mg of MTX/week 
that was approved by a gastroenterologist. No im-
pairment of liver function during nine months of 
treatment was observed. Treatment was termina-
ted because of advanced pulmonary fibrosis with 
minimal active disease, stable CXR image during 
treatment, lack of expected improvement in PFT, 
and active HCV infection. Interferon therapy for 
HCV infection was planned, but severe progression 
of sarcoidosis after MTX withdrawal was diagnosed 
as an important contraindication for such treatment.
The MTX therapy proved to be safe in pa-
tients with initial laboratory impairment of he-
patic function of different origin (including ste-
atosis), hepatic sarcoidosis confirmed by biopsy, 
and in patients with active HCV infection. In 
one patient alcohol abuse was the cause of liver 
test abnormalities and led to treatment discon-
tinuation.
We confirmed that the most common side 
effects of MTX were minor hepatic laboratory 
abnormalities that usually resolve. Most of our 
patients experienced an increase in serum ALT 
and bilirubin concentrations, as was described 
by other researchers [2, 40]. Lower et al. ob-
served that the mean alkaline phosphatase (ALP) 
concentration is significantly higher in patients 
with sarcoidosis and MTX toxicity (confirmed 
by hepatic biopsy), but they did not find any li-
ver function test result that would predict MTX 
toxicity [8]. We did not observe in our cohort any 
significant changes in ALP concentrations during 
MTX therapy or after drug withdrawal because 
of mild hepatotoxicity. 
The most serious reactions we noted were lo-
wer respiratory tract infections, including two ca-
ses of tuberculosis (TB). Evidence of a relation be-
tween sarcoidosis and mycobacterial infections has 
been provided by long-term clinical studies [41]. 
The follow-up of M. tuberculosis DNA-positive 
sarcoid patients showed that they are not at 
greater risk of developing tuberculosis, even on 
steroid therapy [42]. In both TB patients several 
sputum and BAL fluid cultures were negatives 
for Bacilli Koch (BK) before starting the MTX 
treatment. TB developed during immunosuppres-
sive therapy with MTX and was the reason for 
drug withdrawal. Although successfully treated 
with an anti-TB regimen, both patients experien-
ced serious sarcoidosis progression after MTX 
withdrawal with PFT deterioration that needed 
steroid therapy. We would advise monitoring of 
all immunosuppressed patients closely and con-
sideration of TB infection even if mild clinical 
symptoms occur.
Conclusions
MTX as a single agent in the treatment of 
sarcoidosis has proven to be a safe and effective 
steroid alternative. Selected sarcoid patients with 
chronic progressive sarcoidosis experience defini-
te PFT improvement after MTX treatment. There 
is a need to define predictors of MTX treatment 
effectiveness.
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